Dongxing Securities

Yuexiu REIT's Revenue Up by 11.4% for 2023

Retrieved on: 
Thursday, March 7, 2024

HONG KONG, Mar 7, 2024 - (ACN Newswire) - Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the ?REIT?

Key Points: 
  • HONG KONG, Mar 7, 2024 - (ACN Newswire) - Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the ?REIT?
  • -- Operating revenue of the GZIFC complex was RMB1,031 million, accounting for 49.4% of the REIT's total revenue.
  • -- Yuexiu Financial Tower posted an operating revenue of approximately RMB399 million, representing 19.1% of the REIT's total revenue.
  • GZIFC and Yuexiu Financial Tower completed the renewal of Platinum Certification, and Wuhan Yuexiu Fortune Centre obtained the Net Zero Carbon Building Excellence Certification.

2021 Bio-enzyme Application Explorer Summit held in Chengdu

Retrieved on: 
Friday, October 22, 2021

CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment in China and abroad. On October 15, the first Bio-enzyme Application Explorer Summit was held in Chengdu under the theme of "Dare to Dream, Dare to Take on Responsibilities". The summit was organized by Sichuan Deebiotech Co., Ltd., a global expert in bio-enzyme production and R&D, with the aim of promoting the innovative development of the biochemical pharmaceutical industry. 

Key Points: 
  • On October 15, the first Bio-enzyme Application Explorer Summit was held in Chengdu under the theme of "Dare to Dream, Dare to Take on Responsibilities".
  • For this reason, the first Bio-enzyme Application Explorer Summit organized by Sichuan Deebiotech is of great significance to driving the development of the biochemical pharmaceutical industry.
  • "Therefore, opening a broader space for the application of pharmaceutical bio-enzymes is the key to the development of bio-enzymes enterprises.
  • The Bio-enzyme Application Explorer Summit is not only a great event for industry pioneers and builders, but also a milestone event for Deebiotech to continue its in-depth expansion in the field of bio-enzymes.

Glory Star Announces Research Coverage Initiated by Dongxing Securities, With US$6.05 Price Target

Retrieved on: 
Tuesday, July 27, 2021

BEIJING, July 27, 2021 (GLOBE NEWSWIRE) -- Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) ("Glory Star" or the "Company"), a leading digital media platform and content-driven e-commerce company in China, today announced that Dongxing Securities (Hong Kong) has initiated research coverage of Glory Star with price to sales ratio (TTM) of 2.21, a corresponding price target of US$6.05 per share, and a rational valuation of US$409 million.

Key Points: 
  • BEIJING, July 27, 2021 (GLOBE NEWSWIRE) -- Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) ("Glory Star" or the "Company"), a leading digital media platform and content-driven e-commerce company in China, today announced that Dongxing Securities (Hong Kong) has initiated research coverage of Glory Star with price to sales ratio (TTM) of 2.21, a corresponding price target of US$6.05 per share, and a rational valuation of US$409 million.
  • Please note that any opinions, estimates, or forecasts regarding the performance of Glory Star and its management made by Dongxing Securities are theirs alone and do not represent the opinions, estimates, or forecasts of Glory Star or its management.
  • Glory Star does not by this announcement or otherwise imply that the Company analyzes or approves of such information, conclusions, or recommendations.
  • Glory Star New Media Group Holdings Limited is a leading digital media platform and content-driven e-commerce company in China.